Recent Updates — ITGR
Integer Holdings Corporation reported third-quarter 2026 results with total sales decreasing 3.9% to $450 million and non-GAAP adjusted earnings per share falling 25% to $1.34. GAAP diluted EPS was $0.43, down from $1.11 in the prior year period. The company is not providing a financial outlook or hosting a conference call due to its pending acquisition by an affiliate of KKR. Stockholders approved the merger agreement on October 21, and regulatory clearance under the Hart-Scott-Rodino Act was received on September 29. The transaction is anticipated to close by the end of 2026, subject to customary closing conditions. Integer Holdings Corporation operates as a medical device contract development and manufacturing organization (CDMO).
Stockholders of Integer Holdings Corporation approved the Merger Agreement with Armstrong Parent, Inc., an affiliate of Kohlberg Kravis Roberts & Co. L.P., at a special meeting on October 21, 2026. Approximately 76.7% of outstanding shares voted in favor, with nearly all votes cast supporting the transaction. The acquisition is expected to close by the end of 2026, subject to customary closing conditions and regulatory approvals. Integer Holdings Corporation operates as a global medical device contract development and manufacturing organization (CDMO).
Integer Holdings Corporation filed a current report to voluntarily supplement its definitive proxy statement regarding the proposed merger with Armstrong Bidco, Inc., an affiliate of Kohlberg Kravis Roberts & Co. (KKR). The filing discloses that Goldman Sachs derived illustrative equity values per share ranging from $98.93 to $140.68 based on a discounted cash flow analysis and approximately 35 million fully diluted shares. This disclosure follows the filing of three lawsuits by stockholders alleging misleading descriptions in the proxy statement, alongside demand letters from attorneys representing thirteen purported stockholders seeking to enjoin the transaction. The special meeting to vote on the merger is scheduled for October 21, 2026. Integer Holdings Corporation operates in the medical device industry, designing and manufacturing products for surgical procedures.
Integer Holdings Corporation announced that holders of its 2.125% Convertible Senior Notes due 2028 may convert the notes during the calendar quarter ending December 31, 2026. The conversion option became available because the stock price exceeded 130% of the conversion price for at least 20 trading days within a 30-day period ending September 30, 2026. Notes convert at a rate of 11.4681 shares per $1,000 principal amount, equivalent to an approximate conversion price of $87.20 per share. Settlement is in cash up to the principal amount, with the company electing cash or stock for any excess obligation. Integer Holdings Corporation operates as a medical device contract development and manufacturing organization (CDMO).
Integer Holdings Corporation announced on September 30, 2026, that it received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its pending acquisition by an affiliate of Kohlberg Kravis Roberts & Co. L.P. (KKR). The transaction values Integer at $127 per share in cash, representing a total enterprise value of approximately $5.7 billion. This regulatory milestone satisfies one condition to closing the merger, which remains subject to stockholder approval and other customary conditions. A special meeting of stockholders is scheduled for October 21, 2026, where the board unanimously recommends voting in favor of the agreement. The company expects the transaction to close by the end of calendar year 2026. Integer Holdings Corporation operates as a global medical device contract development and manufacturing organization (CDMO).
On August 2, 2026, Integer Holdings Corporation entered into a definitive Agreement and Plan of Merger with Armstrong Parent, Inc., an affiliate of Kohlberg Kravis Roberts & Co. L.P. (KKR). Under the terms of the transaction, KKR will acquire Integer Holdings in an all-cash deal valued at $127 per share for outstanding common stock. The merger is subject to customary closing conditions, including stockholder approval and antitrust clearances under the Hart-Scott-Rodino Act, with an outside date of May 2, 2027. Financing commitments have been secured from KKR funds and third-party lenders. Termination fees are set at $154 million payable by Integer Holdings for certain terminations and $307 million payable by Parent for breach or failure to close. The company operates in the medical device industry, manufacturing surgical instruments and implants.